Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum

cardiovascular disease

  • You have accessRestricted Access
    Authors’ Reply
    An S. De Vriese
    JASN September 2021, 32 (9) 2390-2391; DOI: https://doi.org/10.1681/ASN.2021060866
    Add to Selected Citations
  • You have accessRestricted Access
    Circulating Soluble Fms-like Tyrosine Kinase in Renal Diseases Other than Preeclampsia
    Theresa M. Wewers, Annika Schulz, Ingo Nolte, Hermann Pavenstädt, Marcus Brand and Giovana S. Di Marco
    JASN August 2021, 32 (8) 1853-1863; DOI: https://doi.org/10.1681/ASN.2020111579
    Add to Selected Citations
  • Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial
    You have accessRestricted Access
    Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial
    An S. De Vriese, Rogier Caluwé, Hans Van Der Meersch, Koen De Boeck and Dirk De Bacquer
    JASN June 2021, 32 (6) 1474-1483; DOI: https://doi.org/10.1681/ASN.2020111566
    Add to Selected Citations
  • BP in Young Adults with CKD and Associations with Cardiovascular Events and Decline in Kidney Function
    You have accessRestricted Access
    BP in Young Adults with CKD and Associations with Cardiovascular Events and Decline in Kidney Function
    Alexander J. Kula, David K. Prince, Joseph T. Flynn and Nisha Bansal
    JASN May 2021, 32 (5) 1200-1209; DOI: https://doi.org/10.1681/ASN.2020081156
    Add to Selected Citations
  • Effect of Kidney Function on Relationships between Lifestyle Behaviors and Mortality or Cardiovascular Outcomes: A Pooled Cohort Analysis
    You have accessRestricted Access
    Effect of Kidney Function on Relationships between Lifestyle Behaviors and Mortality or Cardiovascular Outcomes: A Pooled Cohort Analysis
    Sarah J. Schrauben, Jesse Y. Hsu, Sandra Amaral, Amanda H. Anderson, Harold I. Feldman and Laura M. Dember
    JASN March 2021, 32 (3) 663-675; DOI: https://doi.org/10.1681/ASN.2020040394
    Add to Selected Citations
  • Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
    You have accessRestricted Access
    Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
    Pablo E. Pergola, Matt Devalaraja, Steven Fishbane, Michel Chonchol, Vandana S. Mathur, Mark T. Smith, Larry Lo, Kurt Herzog, Rahul Kakkar and Michael H. Davidson
    JASN January 2021, 32 (1) 211-222; DOI: https://doi.org/10.1681/ASN.2020050595
    Add to Selected Citations
  • Death after Kidney Transplantation: An Analysis by Era and Time Post-Transplant
    You have accessRestricted Access
    Death after Kidney Transplantation: An Analysis by Era and Time Post-Transplant
    Tracey Ying, Bree Shi, Patrick J. Kelly, Helen Pilmore, Philip A. Clayton and Steven J. Chadban
    JASN December 2020, 31 (12) 2887-2899; DOI: https://doi.org/10.1681/ASN.2020050566
    Add to Selected Citations
  • A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD)
    You have accessRestricted Access
    A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD)
    Nigel D. Toussaint, Eugenia Pedagogos, Nicole M. Lioufas, Grahame J. Elder, Elaine M. Pascoe, Sunil V. Badve, Andrea Valks, Geoffrey A. Block, Neil Boudville, James D. Cameron, Katrina L. Campbell, Sylvia S.M. Chen, Randall J. Faull, Stephen G. Holt, Dana Jackson, Meg J. Jardine, David W. Johnson, Peter G. Kerr, Kenneth K. Lau, Lai-Seong Hooi, Om Narayan, Vlado Perkovic, Kevan R. Polkinghorne, Carol A. Pollock, Donna Reidlinger, Laura Robison, Edward R. Smith, Robert J. Walker, Angela Yee Moon Wang, Carmel M. Hawley and IMPROVE-CKD Trial Investigators
    JASN November 2020, 31 (11) 2653-2666; DOI: https://doi.org/10.1681/ASN.2020040411
    Add to Selected Citations
  • You have accessRestricted Access
    Central Role for Adipocyte Na,K-ATPase Oxidant Amplification Loop in the Pathogenesis of Experimental Uremic Cardiomyopathy
    Komal Sodhi, Xiaoliang Wang, Muhammad Aslam Chaudhry, Hari Vishal Lakhani, Mishghan Zehra, Rebecca Pratt, Athar Nawab, Cameron L. Cottrill, Brian Snoad, Fang Bai, James Denvir, Jiang Liu, Juan R. Sanabria, Zijian Xie, Nader G. Abraham and Joseph I. Shapiro
    JASN August 2020, 31 (8) 1746-1760; DOI: https://doi.org/10.1681/ASN.2019101070
    Add to Selected Citations
  • CKD Increases Carbonylation of HDL and Is Associated with Impaired Antiaggregant Properties
    You have accessRestricted Access
    CKD Increases Carbonylation of HDL and Is Associated with Impaired Antiaggregant Properties
    Nans Florens, Catherine Calzada, Sandrine Lemoine, Marie Michèle Boulet, Nicolas Guillot, Christophe Barba, Julie Roux, Fréderic Delolme, Adeline Page, Jean Michel Poux, Maurice Laville, Philippe Moulin, Laurent Soulère, Fitsum Guebre-Egziabher, Laurent Juillard and Christophe O. Soulage
    JASN July 2020, 31 (7) 1462-1477; DOI: https://doi.org/10.1681/ASN.2019111205
    Add to Selected Citations

Pages

  • Previous
  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire